<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03603756</url>
  </required_header>
  <id_info>
    <org_study_id>NCC201807010</org_study_id>
    <nct_id>NCT03603756</nct_id>
  </id_info>
  <brief_title>SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer</brief_title>
  <official_title>SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with previously untreated advanced or metastatic esophageal squamous cell carcinoma&#xD;
      are recruited to this prospective non-randomized study comprising two separate cohorts.&#xD;
      Patients will receive SHR-1210, a novel anti-PD-1 antibody, with apatinib and either&#xD;
      irinotecan or paclitaxel liposome plus nedaplatin. The primary endpoint is to determine the&#xD;
      objective response rate (ORR) of patients in both cohorts. The regimen(s) of promising&#xD;
      efficacy will be further verified in subsequent randomized studies to define the optimal&#xD;
      combination of immunotherapy, anti-angiogenesis and chemotherapy in advanced esophageal&#xD;
      cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">March 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 28, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>objective response rate</measure>
    <time_frame>24 months</time_frame>
    <description>objective response rate of the patients in cohort 1 and cohort 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>progression-free survival (PFS) of the patients in cohort 1 and cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>24 months</time_frame>
    <description>overall survival of the patients in cohort 1 and cohort 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events</measure>
    <time_frame>24 months</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and irinotecan injection in cohort 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with advanced or metastatic esophageal squamous cell carcinoma are to receive SHR-1210 with apatinib and paclitaxel liposome plus nedaplatin in cohort 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHR-1210</intervention_name>
    <description>a novel anti-PD-1 antibody</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib</intervention_name>
    <description>a VEGFR-2 tyrosine kinase inhibitor</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan Injection</intervention_name>
    <description>cytotoxic agent that binds to topoisomerase I</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel liposome</intervention_name>
    <description>cytotoxic agent that prevent depolymerization of cellular microtubules</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nedaplatin</intervention_name>
    <description>cytotoxic agent that cross-links and denatures strands of DNA</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed squamous cell carcinoma of the esophagus,&#xD;
             locally advanced, unresectable, recurrent or metastatic disease.&#xD;
&#xD;
          2. Have not received prior systemic therapy.&#xD;
&#xD;
          3. Measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) 1.1.&#xD;
&#xD;
          4. Eastern Collaborative Oncology Group (ECOG) Performance Status ≤ 1.&#xD;
&#xD;
          5. Life expectancy &gt;12 weeks.&#xD;
&#xD;
          6. Adequate organ function.&#xD;
&#xD;
          7. For females of child bearing potential, a negative urine or serum pregnancy test&#xD;
             result within 72h before study treatment. Participants of reproductive potential must&#xD;
             be willing to use adequate contraception for the course of the study until 2 months&#xD;
             after the last dose of any of the drugs in the study.&#xD;
&#xD;
          8. Willing and able to provide written informed consent and comply with the requirements&#xD;
             of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any previous malignancy, except for non squamous-cell carcinoma of skin or&#xD;
             carcinoma-in-situ of the uterine cervix within 5 years prior to study entry.&#xD;
&#xD;
          2. Known central nervous system (CNS) metastases.&#xD;
&#xD;
          3. Prior therapy with any of the immune check-point inhibitors.&#xD;
&#xD;
          4. Known immediate or delayed hypersensitivity reaction to SHR-1210, apatinib,&#xD;
             irinotecan, paclitaxel liposome, nedaplatin or their excipients.&#xD;
&#xD;
          5. Subjects with any active autoimmune disease or history of autoimmune disease.&#xD;
&#xD;
          6. Known Human Immunodeficiency Virus (HIV) infection, active Hepatitis B or Hepatitis C&#xD;
             infection.&#xD;
&#xD;
          7. Concurrent medical condition requiring the use of cortisol (&gt;10mg/day prednisone or&#xD;
             equivalent dose) or other systematic immunosuppressive medications within 14 days&#xD;
             before the study treatment. Except: inhalation or topical corticosteroids no more than&#xD;
             10 mg/day prednisone or equivalent.&#xD;
&#xD;
          8. Received a live vaccine within 4 weeks of the first dose of study medication.&#xD;
&#xD;
          9. Hypertension with a blood pressure of systolic&gt; 140 millimeter of mercury (mm Hg)&#xD;
             and/or diastolic &gt; 90 mm Hg that is not effectively controlled by anti-hypertensive&#xD;
             therapy.&#xD;
&#xD;
         10. Uncontrolled clinically significant heart disease, including but not limited to the&#xD;
             following: (1) &gt; NYHA II congestive heart failure; (2) unstable angina, (3) myocardial&#xD;
             infarction within the past 1 year; (4) clinically significant supraventricular&#xD;
             arrhythmia or ventricular arrhythmia requiring treatment or intervention.&#xD;
&#xD;
         11. Unable to swallow oral medications or with gastrointestinal disorders that might&#xD;
             interfere with proper absorption of oral drugs.&#xD;
&#xD;
         12. Active digestive ulcer disease, inflammatory bowel disease, intestinal obstruction or&#xD;
             any other condition that, in the clinical judgment of the Principal Investigator, may&#xD;
             cause severe gastrointestinal bleeding or perforation.&#xD;
&#xD;
         13. Active infection or an unexplained fever &gt; 38.5°C before 4 weeks of enrollment.&#xD;
&#xD;
         14. Unstable pulmonary embolism, deep vein thrombosis, or other significant&#xD;
             arterial/venous thromboembolic conditions.&#xD;
&#xD;
         15. Pregnant or lactating female.&#xD;
&#xD;
         16. Familial, sociological or geographical conditions that, in the clinical judgment of&#xD;
             the Principal Investigator, do not permit compliance with the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing Huang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital,CAMS</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jing Huang, MD</last_name>
    <phone>86-10-87788102</phone>
    <email>huangjingwg@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jianping Xu, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Jing Huang</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Huang, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 20, 2018</study_first_submitted>
  <study_first_submitted_qc>July 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2018</study_first_posted>
  <last_update_submitted>February 9, 2020</last_update_submitted>
  <last_update_submitted_qc>February 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jing Huang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Neoplasms, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Nedaplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

